Vivoss Therapeutics Partners With SPCVA to Expand Cardiovascular Sleep Services

Vivoss Therapeutics (VVOS) announced on June 16 a partnership with South Palm Cardiovascular Associates (SPCVA) to expand sleep apnea and insomnia diagnosis and treatment for cardiovascular patients in Florida. The collaboration establishes AIM Florida, a management service organization designed to integrate sleep disorder care within cardiology practices to reduce cardiovascular risks.

How will AIM Florida operate?

The organization will launch in Palm Beach County, Florida. Cardiologists at SPCVA will use the system to increase patient access to sleep apnea treatments, which are linked to cardiovascular health, according to the company announcement.

CEO Kirk Huntsman described the partnership as an innovative model that avoids the heavy capital investment typical of mergers and acquisitions. Instead, the company is forming direct partnerships with medical communities.

Did You Know? Vivoss Therapeutics identifies a potential expansion path to approximately 2,500 similar cardiology groups across the United States.

What are the financial goals of the collaboration?

AIM Florida aims to deploy an initial sleep optimization team. This team intends to treat 250 patients per month to reach annual revenues exceeding $6 million, according to company targets.

Vivoss Therapeutics expects a contribution margin of approximately 50% from this model. The company intends to scale by adding more teams over time.

Expert Insight: Samantha Carter notes that shifting from traditional acquisitions to a partnership-based management model allows a company to scale its clinical footprint rapidly without the balance sheet strain of buying practices outright.

What are the long-term projections and risks?

Market projections suggest Vivoss Therapeutics’ revenue could grow to $22.97 million in 2026, a 31.74% increase over the previous year. Revenue may further rise to $39.51 million in 2027, representing a 71.96% increase.

Despite revenue growth, earnings per share (EPS) are expected to remain negative. Projections show an EPS of -$1.5 in 2026 and -$0.175 in 2027. Analysts suggest the new partnership model could improve the company’s cash flow and overall profitability.

The company noted that the contract and business commencement are not yet finalized. Terms and schedules remain subject to change. All clinical decisions and patient care will continue to be handled independently by medical professionals in compliance with state and federal health laws.

Frequently Asked Questions

What is the primary goal of the AIM Florida organization?
The goal is to provide integrated diagnosis and treatment services for patients with sleep disorders associated with cardiovascular disease.

How does this model differ from previous growth strategies?
CEO Kirk Huntsman stated this model reduces capital investment burdens compared to traditional mergers and acquisitions.

Is the partnership currently operational?
The company stated that the contract execution and business start date are not yet finalized and may change.

How might the integration of sleep medicine into cardiology practices change patient outcomes for cardiovascular disease?